172 related articles for article (PubMed ID: 38599013)
21. Ceftazidime-avibactam alone or in combination with Aztreonam versus Polymyxins in the management of carbapenem-Resistant Klebsiella pneumoniae nosocomial Infections (CAPRI study): a retrospective cohort study from South India.
Sree RA; Gupta A; Gupta N; Veturi S; Reddy LSK; Begum M; Shravani E; Challa HR; Reddy SS; Singamsetty A; Arumilli M; Reddy PN; Tirlangi PK
Infection; 2024 Apr; 52(2):429-437. PubMed ID: 37697224
[TBL] [Abstract][Full Text] [Related]
22.
Li X; Chen Z; Jiao J; Wang S; Wang Y; Wu W; Yang H; Lou H
Expert Rev Anti Infect Ther; 2023 Jan; 21(1):91-98. PubMed ID: 36433637
[TBL] [Abstract][Full Text] [Related]
23. The Potential Use of Ceftazidime-Avibactam Against Carbapenem Resistant
Nasomsong W; Nulsopapon P; Changpradub D; Pongchaidecha M; Pungcharoenkijkul S; Juntanawiwat P; Simsiriporn W; Santimaleeworagun W
Drug Des Devel Ther; 2021; 15():3095-3104. PubMed ID: 34295150
[TBL] [Abstract][Full Text] [Related]
24. Activity of Ceftazidime-Avibactam Against Clinical Isolates of Klebsiella pneumoniae, Including KPC-Carrying Isolates, Endemic to New York City.
Manning N; Balabanian G; Rose M; Landman D; Quale J
Microb Drug Resist; 2018; 24(1):35-39. PubMed ID: 28590820
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the synergy of ceftazidime/avibactam in combination with colistin, doripenem, levofloxacin, tigecycline, and tobramycin against OXA-48 producing Enterobacterales.
Mataraci Kara E; Yilmaz M; Istanbullu Tosun A; Özbek Çelik B
J Chemother; 2020 Jul; 32(4):171-178. PubMed ID: 32375606
[TBL] [Abstract][Full Text] [Related]
26. Geographic patterns of global isolates of carbapenem-resistant Klebsiella pneumoniae and the activity of ceftazidime/avibactam, meropenem/vaborbactam, and comparators against these isolates: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2020.
Lee YL; Ko WC; Hsueh PR
Int J Antimicrob Agents; 2022; 60(5-6):106679. PubMed ID: 36241011
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics and Efficacy of Ceftazidime-Avibactam in the Treatment of Experimental Pneumonia Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Persistently Neutropenic Rabbits.
Petraitiene R; Petraitis V; Kavaliauskas P; Maung BBW; Khan F; Naing E; Aung T; Zigmantaite V; Grigaleviciute R; Kucinskas A; Stakauskas R; Georgiades BN; Mazur CA; Hayden JA; Satlin MJ; Walsh TJ
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015048
[No Abstract] [Full Text] [Related]
28. Carbapenemase producing
Karaiskos I; Galani I; Papoutsaki V; Galani L; Giamarellou H
Expert Rev Anti Infect Ther; 2022 Jan; 20(1):53-69. PubMed ID: 34033499
[TBL] [Abstract][Full Text] [Related]
29. Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and β-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values.
Castanheira M; Doyle TB; Hubler C; Sader HS; Mendes RE
Int J Antimicrob Agents; 2020 Jul; 56(1):106011. PubMed ID: 32417206
[TBL] [Abstract][Full Text] [Related]
30. Activity of Cefiderocol, Ceftazidime-Avibactam, and Eravacycline against Carbapenem-Resistant Escherichia coli Isolates from the United States and International Sites in Relation to Clonal Background, Resistance Genes, Coresistance, and Region.
Johnston BD; Thuras P; Porter SB; Anacker M; VonBank B; Snippes Vagnone P; Witwer M; Castanheira M; Johnson JR
Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32718965
[TBL] [Abstract][Full Text] [Related]
31. Emergence of Ceftazidime/Avibactam and Tigecycline Resistance in Carbapenem-Resistant
Han X; Shi Q; Mao Y; Quan J; Zhang P; Lan P; Jiang Y; Zhao D; Wu X; Hua X; Yu Y
Front Cell Infect Microbiol; 2021; 11():757470. PubMed ID: 34760723
[No Abstract] [Full Text] [Related]
32.
Yu F; Lv J; Niu S; Du H; Tang YW; Bonomo RA; Kreiswirth BN; Chen L
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29891605
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of ceftazidime-avibactam compared to other antimicrobials for the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae strains, a systematic review and meta-analysis.
Karampatakis T; Tsergouli K; Lowrie K
Microb Pathog; 2023 Jun; 179():106090. PubMed ID: 37004964
[TBL] [Abstract][Full Text] [Related]
34. Molecular Mechanisms Driving the
Li X; Ke H; Wu W; Tu Y; Zhou H; Yu Y
mSphere; 2021 Dec; 6(6):e0085921. PubMed ID: 34935448
[TBL] [Abstract][Full Text] [Related]
35. In-vitro activity of cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline and other comparative agents against carbapenem-nonsusceptible Enterobacterales: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2017-2020.
Lee YL; Ko WC; Lee WS; Lu PL; Chen YH; Cheng SH; Lu MC; Lin CY; Wu TS; Yen MY; Wang LS; Liu CP; Shao PL; Shi ZY; Chen YS; Wang FD; Tseng SH; Lin CN; Chen YH; Sheng WH; Lee CM; Tang HJ; Hsueh PR
Int J Antimicrob Agents; 2021 Sep; 58(3):106377. PubMed ID: 34166777
[TBL] [Abstract][Full Text] [Related]
36. Emergence of KPC-2 and NDM-5-coproducing hypervirulent carbapenem-resistant
Zhou Y; Wu X; Wu C; Zhou P; Yang Y; Wang B; Xu Y; Zhao H; Guo Y; Yu J; Yu F
mSphere; 2024 Jan; 9(1):e0061223. PubMed ID: 38193656
[TBL] [Abstract][Full Text] [Related]
37. Comparative Activities of Novel Therapeutic Agents against Molecularly Characterized Clinical Carbapenem-Resistant
Teo JQ; Chang HY; Tan SH; Tang CY; Ong RT; Ko KKK; Chung SJ; Tan TT; Kwa AL
Microbiol Spectr; 2023 Jun; 11(3):e0100223. PubMed ID: 37184408
[TBL] [Abstract][Full Text] [Related]
38. Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime/avibactam.
Papadimitriou-Olivgeris M; Bartzavali C; Lambropoulou A; Solomou A; Tsiata E; Anastassiou ED; Fligou F; Marangos M; Spiliopoulou I; Christofidou M
J Antimicrob Chemother; 2019 Jul; 74(7):2051-2054. PubMed ID: 31002313
[TBL] [Abstract][Full Text] [Related]
39. Will ceftazidime/avibactam plus aztreonam be effective for NDM and OXA-48-Like producing organisms: Lessons learnt from
Pragasam AK; Veeraraghavan B; Shankar BA; Bakthavatchalam YD; Mathuram A; George B; Chacko B; Korula P; Anandan S
Indian J Med Microbiol; 2019; 37(1):34-41. PubMed ID: 31424008
[TBL] [Abstract][Full Text] [Related]
40. Emergence of Hypervirulent ST11-K64
Wei T; Zou C; Qin J; Tao J; Yan L; Wang J; Du H; Shen F; Zhao Y; Wang H
Front Public Health; 2022; 10():765624. PubMed ID: 35309213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]